Comparison between Amagi Media Labs IPO and Nephrocare Health IPO.
Amagi Media Labs IPO is a Mainboard Bookbuilding IPO proposed to list at BSE, NSE while Nephrocare Health IPO is a Mainboard Bookbuilding proposed to list at BSE, NSE.
The total issue size of Amagi Media Labs IPO is up to ₹1,788.62 Cr whereas the issue size of the Nephrocare Health IPO is up to ₹871.05 Cr. The final issue price of Amagi Media Labs IPO is ₹361.00 per share and of Nephrocare Health IPO is ₹460.00 per share.
| Amagi Media Labs IPO | Nephrocare Health IPO | |
|---|---|---|
| Face Value | ₹5 per share | ₹2 per share |
| Issue Price (Lower) | ₹343.00 per share | ₹438.00 per share |
| Issue Price (Upper) | ₹361.00 per share | ₹460.00 per share |
| Issue Price (Final) | ₹361.00 per share | ₹460.00 per share |
| Discount (Retail) | ||
| Discount (Employee) | ₹41.00 per share | |
| Market Lot Size | 41 shares | 32 shares |
| Fresh Issue Size | 2,26,03,878 shares | 76,89,918 shares |
| Fresh Issue Size (Amount) | up to ₹816.00 Cr | up to ₹353.60 Cr |
| OFS Issue Size | 2,69,42,343 shares | 1,12,53,102 shares |
| OFS Issue Size (Amount) | up to ₹972.62 Cr | up to ₹517.45 Cr |
| Issue Size Total | 4,95,46,221 shares | 1,89,43,020 shares |
| Issue Size Total (Amount) | up to ₹1,788.62 Cr | up to ₹871.05 Cr |
Amagi Media Labs IPO opens on Jan 13, 2026, while Nephrocare Health IPO opens on Dec 10, 2025. The closing date of Amagi Media Labs IPO and Nephrocare Health IPO is Jan 16, 2026, and Dec 12, 2025, respectively.
| Amagi Media Labs IPO | Nephrocare Health IPO | |
|---|---|---|
| Anchor Bid Date | Jan 12, 2026 | Dec 09, 2025 |
| Issue Open | Jan 13, 2026 | Dec 10, 2025 |
| Issue Close | Jan 16, 2026 | Dec 12, 2025 |
| Basis Of Allotment (Tentative) | Jan 19, 2026 | Dec 15, 2025 |
| Initiation of Refunds (Tentative) | Jan 20, 2026 | Dec 16, 2025 |
| Credit of Share (Tentative) | Jan 20, 2026 | Dec 16, 2025 |
| Listing date (Tentative) | Jan 21, 2026 | Dec 17, 2025 |
| Anchor Lockin End date 1 | Feb 17, 2026 | Jan 13, 2026 |
| Anchor Lockin End date 2 | Apr 18, 2026 | Mar 14, 2026 |
Amagi Media Labs IPO P/E ratio is -101.78, as compared to Nephrocare Health IPO P/E ratio of 63.52.
| Amagi Media Labs IPO | Nephrocare Health IPO | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Financials | Company Financials (Restated Consolidated)
| Company Financials (Restated Consolidated)Nephrocare Health Services Ltd.'s revenue increased by 34% and profit after tax (PAT) rose by 91% between the financial year ending with March 31, 2025 and March 31, 2024.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Pre-Issue) | 15.76 | 78.90 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Post-Issue) | 14.14 | 71.49 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| P/E Ratio | -101.78 | 63.52 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Market Cap | ₹7809.84 Cr. | ₹4615.34 Cr. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROE | 13.45% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROCE | 18.67% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Debt/Equity | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EPS | ₹-3.55 | ₹7.24 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| RoNW | -13.49% | 13.19% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
In the Amagi Media Labs IPO Retail Individual Investors (RII) are offered 49,54,622 shares while in Nephrocare Health IPO retail investors are offered 49,54,622 shares. Qualified Institutional Buyers (QIB) are offered 1,48,63,867 shares in Amagi Media Labs IPO and 37,71,946 shares in Nephrocare Health IPO.
| Amagi Media Labs IPO | Nephrocare Health IPO | |
|---|---|---|
| Anchor Investor Reservation | 2,22,95,799 shares | 56,57,919 shares |
| Market Maker Reservation | 0 shares | 0 shares |
| QIB | 1,48,63,867 shares | 37,71,946 shares |
| NII | 74,31,933 shares | 28,28,960 shares |
| RII | 49,54,622 shares | 66,00,907 shares |
| Employee | 0 shares | 83,532 shares |
| Others | ||
| Total | 4,95,46,221 shares | 1,89,43,264 shares |
Amagi Media Labs IPO subscribed 30.24x in total, whereas Nephrocare Health IPO subscribed 14.08x.
| Amagi Media Labs IPO | Nephrocare Health IPO | |
|---|---|---|
| QIB (times) | 33.13x | 26.82x |
| NII (times) | 38.26x | 24.77x |
| Big NII (times) | 44.24x | 30.43x |
| Small NII (times) | 26.29x | 13.46x |
| RII (times) | 9.54x | 2.36x |
| Employee (times) | 2.81x | |
| Other (times) | ||
| Total (times) | 30.24x | 14.08x |
